Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

ConclusionsWe provide novel insight into the mechanism of action of N-803 plus anti-PD-L1 combination and offer preclinical proof of concept supporting clinical use of N-803 in combination with checkpoint inhibitors, including for patients non- and/or minimally responsive to either monotherapy.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research